

BREAKTHROUGH PAVES WAY FOR NEW LYME DISEASE TREATMENT


Brandon L. Jutras et al.,

"*Borrelia burgdorferi* peptidoglycan is a persistent antigen in patients with Lyme arthritis," PNAS (2019)

MEDSCAPE NEWS – JUNE 2019

A deer tick (left), one of the species of tick that transmits the bacteria that causes Lyme disease. High resolution fluorescently tagged image of the bacteria *B. burgdorferi* that causes Lyme disease (right).

Credit: Virginia Tech / Brandon Jutras



The discovery

- ▣ A cellular component contributes to **Lyme arthritis**, a debilitating and extremely painful condition that is the most common late stage symptom of Lyme disease
- ▣ As the Lyme-causing bacteria *Borrelia burgdorferi* multiplies, it sheds a cellular component called **peptidoglycan** that elicits a unique inflammatory response in the body

The message



- ▣ “This discovery will help researchers improve diagnostic tests
- ▣ and may lead to new treatment options for patients suffering with Lyme arthritis”
- ▣ “This is an important finding, and we think that it has major implications for many manifestations of Lyme disease, not just Lyme arthritis”

The message



- ▣ **Peptidoglycan**: essential component of bacterial cell walls
- ▣ All bacteria have some form of peptidoglycan
- ▣ The form found in the bacteria that causes Lyme, *Borrelia burgdorferi*, has a **unique chemical structure**
- ▣ When the bacteria multiply, they shed peptidoglycan into the extracellular environment, because its genome does not have the appropriate proteins to recycle it back into the cell

Explanations



- ▣ We can detect peptidoglycan in the **synovial fluid** of the inflamed joints of patients that have all the symptoms of Lyme arthritis but no longer have an obvious, active infection
- ▣ Peptidoglycan elicits an **inflammatory response** and *the molecule persists in the synovial fluid*
- ▣ **Which means that our bodies continue to respond...**
- ▣ Receptors in our **immune system** sense bacterial products and determine a patient's body reacts to peptidoglycan

Perspectives



- ❑ The next phase of Jutras' work is:
 - ❑ to use methods to destroy the peptidoglycan
 - ❑ or intervene to prevent a response, which could get rid of Lyme disease symptoms
- ❑ Jutras: with either therapy patients would start recovering sooner

Clinical and Lab Study

- ❑ Clinical samples: patients that had **confirmed cases of Lyme disease** (CDC Guidelines), but all did not respond to oral and/or intravenous antibiotic treatment
- ❑ The presence of peptidoglycan in these patients' synovial fluids may explain why some people experience symptoms of late stage Lyme disease **in the absence of an obvious infection**
- ❑ In this case, the usual antibiotic treatments for Lyme disease would no longer be helpful !

More studies on mice

- ❑ Members of the Jacobs-Wagner lab purified the peptidoglycan and removed all other bacterial components and asked
- ❑ *Is peptidoglycan **all on its own** capable of causing arthritis in a mouse model?*
- ❑ Within 24 hours post-injection, mice presented with dramatic joint inflammation, **indicating that peptidoglycan can cause arthritis**

Aldri gi opp!!!



Latterkula.no